Medical Cannabis in the UK: Legalisation, Unequal Access and Human Rights
Lydia Kitchen
Drug Science
Wednesday 05 Aug 2026
Since 2018, cannabis-based products for medicinal use have been available on prescription in the UK. However, NHS access remains exceptionally limited. NHS figures reported to Parliament show that fewer than five patients have received prescriptions for unlicensed products, while more than 1.4 million people are estimated to use cannabis for medical purposes. Private clinics are the main lawful route outside the NHS, but many cannot afford the ongoing costs. People outside the prescription system may still rely on cannabis to manage their health and risk criminalisation.
My recent article in Amicus Curiae, Barriers to Medical Cannabis in the UK: Human Rights Implications of Criminalization and Inequitable Access, examines the gap between legal recognition and practical access from a human rights perspective. It considers whether criminalisation can be justified when people use cannabis therapeutically but cannot obtain a prescription. The central issue is who the system protects and who it leaves exposed to criminalisation. Income, disability and gender can shape access to a prescription, while racial inequalities in drug law enforcement affect who bears the consequences of remaining outside it. A legal distinction shaped by these inequalities becomes increasingly difficult to justify.
Legalisation Without Meaningful Access
In 2018, the law changed to allow specialist doctors to prescribe cannabis-based products for medicinal use. This created a lawful route to treatment, although access remains tightly restricted. A small number of licensed cannabis-based medicines are available through the NHS for certain forms of severe epilepsy, chemotherapy-induced nausea and vomiting, and spasticity caused by multiple sclerosis. Private treatment largely involves unlicensed products, including cannabis flower and oils, which are closer to the forms commonly used outside the prescription system. They can be prescribed lawfully, but NHS access is almost non-existent because NICE guidance shapes NHS prescribing and does not recommend them for routine use.
NICE follows established evidence standards that place substantial weight on randomised controlled trials. These remain important, but cannabis can be difficult to assess through this model. Unlike single-compound medicines, cannabis-based products contain varying combinations of active compounds and may affect patients differently, while psychoactive effects can reveal whether participants received the active treatment. Real-world evidence can therefore complement clinical trials. Drug Science’s Project Twenty21 collected longitudinal data from more than 4,500 patients prescribed cannabis for a range of conditions, yet evidence of this kind still carries less weight in NICE guidance.
A 2019 NHS England review identified gaps in specialist education, governance processes, funding and supply as barriers to NHS prescribing. Private clinics remain the main lawful route to unlicensed products, but access requires specialist assessment, medical records, a diagnosis and evidence that conventional treatments have been tried. This can be especially restrictive for conditions such as endometriosis, which takes an average of nine years and four months to diagnose in the UK. Patients may therefore manage symptoms for years before meeting these requirements.
For those who qualify and can sustain the costs, a prescription provides lawful access and protection from possession offences. Without one, possession remains an offence under the Misuse of Drugs Act 1971. Therapeutic use alone is not a defence, so two people may use cannabis for similar health reasons while only the prescribed patient is protected from criminal sanction.
How Limited Access Deepens Inequality
Limited access does not affect everyone in the same way. Private prescriptions can cost hundreds of pounds each month once medication, consultations and clinic charges are included. For people whose health affects their ability to work or creates additional costs, private treatment may be particularly difficult to sustain. Those needing ongoing treatment may therefore be among the least able to pay for lawful access.
Outside the prescription system, criminalisation compounds that disadvantage. A conviction can affect employment, housing and social inclusion. There is also the immediate stress of relying on something illegal to manage a health condition. Patients prescribed cannabis have reported that, despite legal protection, prohibition still produces stigma and anxiety around using medication in public.
These harms are not distributed equally. Research in England and Wales has consistently documented that Black people are disproportionately stopped and searched, prosecuted and convicted for drug offences, including cannabis possession. The ability to pay privately therefore shapes access to legal protection within an already unequal enforcement system.
People with disabilities and chronic illnesses may face lower incomes and additional costs. Those growing cannabis for medical reasons have described how failures in conventional care, criminalisation and reliance on illicit markets can overlap. Women face related barriers because endometriosis and fibromyalgia disproportionately affect them, while diagnosis can take years and effective treatments remain limited. If lawful access depends on diagnosis and previous treatment, existing healthcare inequalities can influence who receives legal protection.
Intersectionality helps explain how income, race, gender and disability can interact so that one person faces several barriers at once, affecting both access to a prescription and exposure to criminalisation. Equality cannot be understood simply as applying the same criminal law to everyone. A rule may appear neutral while placing a heavier burden on groups already disadvantaged. Where lawful protection is unequally accessible, treating everyone outside the prescription system in the same way can reinforce those inequalities.
Autonomy, Equality and Criminalisation
Restricted access and continued criminalisation raise questions about autonomy and equality under the European Convention on Human Rights. Although the Convention does not create a specific right to medical cannabis or guarantee access to a chosen treatment, the current framework must still comply with the rights it protects.
Article 8 protects private life, including personal autonomy, self-determination and bodily integrity. Criminal law is a serious form of state interference in decisions about managing a health condition. The risk of arrest or prosecution can affect how cannabis is obtained and used, discourage disclosure to healthcare professionals and add to the anxiety of managing a condition outside the law. However, Article 8 is not absolute. Governments may interfere with private life to protect public health, but any interference must be lawful, necessary and proportionate. The 2018 reforms make blanket criminalisation harder to justify because the law now recognises cannabis as a legitimate medical treatment. Someone outside the prescription system can still be criminalised without considering why they use cannabis or why a prescription was unavailable. Concerns about unregulated cannabis remain relevant, but they must be weighed against the harms of criminalisation and less restrictive alternatives.
Article 14 prohibits discrimination in the enjoyment of Convention rights, including Article 8. This includes indirect discrimination, where an apparently neutral rule has disproportionately harmful effects. A prescribed patient and someone outside the prescription system may be managing comparable health problems, yet only one is protected from criminal sanction. Access to a prescription can depend on income, diagnosis, previous treatment and the ability to navigate specialist private healthcare. These barriers interact with disability, gender and socioeconomic disadvantage, while those outside the lawful system also face racial inequalities in drug enforcement. The European Court of Human Rights gives particular weight to discrimination involving disability and health status, recognising that vulnerable groups may require stronger protection. Where access has been shaped by structural disadvantage, criminalisation cannot easily be treated as an individual choice not to comply with the law.
Governments have considerable discretion over health policy and public spending, making it difficult to argue that human rights law requires universal NHS provision. Human rights principles nevertheless strengthen the case for Parliament to reform the law. Decriminalising possession is narrower than universal NHS provision and offers the most realistic starting point for a rights-based approach.
Formal Decriminalisation and Wider Reform
Here, decriminalisation means removing possession for personal use from criminal law. It would not create a commercial market or remove controls on production and supply. Some police forces already use diversion schemes and other out-of-court responses for low-level possession. These may prevent prosecution, but the offence remains. Protection therefore depends on local practice and police discretion, creating inconsistency and legal uncertainty.
Legislative reform would provide clearer and more consistent protection. Stevens, Eastwood and Douse propose repealing sections 5(1) and 5(2) of the Misuse of Drugs Act 1971. The London Drugs Commission has recommended removing cannabis from that Act so possession would instead fall under the Psychoactive Substances Act 2016, where it is generally not an offence outside custodial settings.
A narrow medical exemption would risk reproducing barriers already present in the prescription system. People may use cannabis for several reasons or recognise its therapeutic value before receiving a formal diagnosis, so medical and recreational use do not always divide neatly. Requiring proof of medical need would disadvantage those whose conditions are difficult to diagnose or whose symptoms have not been taken seriously. Decriminalising possession would avoid making legal protection depend again on medical documentation and healthcare access.
Reform must also address how personal possession is distinguished from supply. Someone using cannabis regularly for a chronic condition may keep a larger quantity to reduce costs, maintain a reliable supply or limit contact with the illicit market. Fixed quantity thresholds could expose therapeutic users to supply allegations even where the cannabis is intended for personal use.
International experience highlights the importance of health and social support alongside legal reform. Portugal, for example, removed criminal penalties for possession of small quantities of drugs for personal use in 2001, alongside investment in treatment, harm reduction and prevention. In the UK, decriminalisation would not expand NHS prescribing or make private treatment affordable. Wider NHS access, better education for healthcare professionals and the police, and further research would still be needed. Reform should also consider expunging previous cannabis possession convictions to address past harms. Decriminalisation would nevertheless be an important first step, preventing people excluded from lawful medical access from also being criminally punished.
Beyond the 2018 Reforms
The 2018 reforms recognised cannabis as a legitimate medical treatment, but legal protection is limited to those able to obtain a prescription. People using cannabis for similar health reasons can therefore face starkly different legal consequences when cost, delayed diagnosis or other healthcare barriers prevent access. The central problem is the relationship between restricted access and continued criminalisation. Decisions about managing illness engage autonomy, while unequal access and enforcement place a heavier burden on those already disadvantaged. Where people unable to obtain lawful treatment remain exposed to criminal sanction, the current framework does not provide equal protection in any meaningful sense.
Decriminalising possession for personal use would remove one of the clearest harms of the current system. Wider reform is still needed to improve NHS access and affordability, support further research and build public and professional understanding. The 2018 reforms should be judged by the protection they provide in practice. Access and criminal justice policy must be addressed together so that people are not punished because lawful treatment was beyond their reach.
